Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for rapid extubation after TURBT in elderly patients
ChiCTR2400093177Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Sep 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sugammadex, neostigmine and atropine in bladder cancer (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Time from administration of reversal agent to extubation. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
Sugammadexneostigmineatropine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2400093177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093177.